Introduction

84
of this family have been characterized in trypanosomatids, including the proline (8)
85
(TcAAAP069), arginine (9,10) (TcAAP3) and lysine (11) (TcAAP7) permeases. A 86 polyamine transporter (12,13) (TcPAT12) has also been characterized in T. cruzi 87 and it probably belongs to the Amino Acid-Polyamine Organocation (APC; TC 
98
The orthologous genes of TcAAAP069 have been characterized in other 99 trypanosomatids. In T. brucei, the orthologous permease TbAAT6 is a low-affinity 100 low-selective transporter for neutral amino acids, including proline (18). The loss of
101
TbAAT6 is sufficient to develop resistance to eflornithine, a drug used to treat with a significant lower cost (26). Some successful drugs repositioned for 129 neglected diseases are eflornithine and miltefosine which were originally discovered for cancer therapy and now are used to treat HAT and leishmaniasis, 131 respectively (27). Considering this information, in this work we performed an in 132 silico screening of a drug database to find compounds structurally related to CV 133 that could also inhibit TcAAAP069 and exert trypanocidal effect with less toxicity.
135
Methods
136
Parasites. Epimastigotes of Y, CL Brener and Dm28c strains (5 x10 6 cells/mL)
137
were cultured at 28 °C in plastic flasks (25 cm 2 ), containing 5 mL of BHT (brain-138 heart infusion-tryptose) medium supplemented with 10% fetal calf serum (FCS), 139 100 U/mL penicillin, 100 g/mL streptomycin and 20 µg/mL hemin (28).
140
Trypomastigotes were obtained from the extracellular medium of VERO infected 141 cells as previously described (17).
142
Cells. VERO cells (African green monkey Kidney, ATCC® CCL-81™) were 143 cultured in MEM medium supplemented with 10% heat inactivated FCS, 0.15% 144 (w/v) NaHCO 3 , 100 U/mL penicillin and 100 U/mL streptomycin at 37ºC in 5% CO 2 . and CV structural analogues, and parasite proliferation was determined after 48 h.
168
Trypanocidal activity in trypomastigotes and amastigotes was performed using 1 169 x10 6 cells/mL in 96-well plates and incubating at 37 C for 24 h in the presence of To further demonstrate that CV specifically interacts with TcAAAP069, the 246 trypanocidal effect of CV was evaluated using the same parasite models (TcWT 247 and Tc069 cultures). The toxicity of CV significantly increased when TcAAAP069 248 was overexpressed as evidenced by a reduction in the IC 50 value of 47-fold 249 compared to wild type controls (0.27 µM ± 0.06 and 12.67 µM ± 2.1, respectively; 250 p<0.0001) (Fig 1b) . All these evidences demonstrate that proline transporter
251
TcAAAP069 is one of the targets of CV. was also performed. According to the obtained docking models, proline, CV and the four analogues bind different residues groups, located within the permease 293 channel while DPS does not appear to bind to any pocket in TcAAAP069 (Fig 3a) . than the natural ligand. All these data are summarized in Table 1 . 
318
The PRO site refers to the groove occupied by the proline pose, comprised by the 319 sequential group of residues 82-87 (GNVGSA), and the CV site refers to the 320 pocket occupied by the CV pose that includes the residues 264-265 (MM), 397-404
321
(SLIGALPA), 407 (M), and 462-474 (IMVVGTLSMVKGL) (Fig 3b) . All the docked Cyproheptadine 52.6 µM ± 2.9 11.3 µM ± 0.6 10.7 µM ± 1.3 9.1 Olanzapine 120.5 µM ± 11.4 54.1 µM ± 2.9 N/A N/A Clofazimine 9.3 µM ± 0.6 2.8 µM ± 0.09 1.1 µM ± 0. synergism degree, from strong to slight synergism (Fig 4a) . The exceptions were Chou-Talalay plot shows the CI and the effect (Fa, fraction affected) produced by each combination point, where 0 means no effect and 1.0 means maximum 422 trypanocidal effect (Fig 4b) . Dose-reduction index (DRI) represents the dose 423 reduction that is allowed in combination for a given degree of effect as compared 424 with the dose of each drug alone. DRI > 1 indicates favorable dose-reduction.
425
Except for the two combinations that did not present a synergistic effect, the DRI 426 values were higher than 1 for all the combinations assayed with values between 427 2.5 and 374.2 for BZL and between 1.2 and 10.4 for LTD-CPH-CFZ (S1 Table) .
428
Altogether, these results suggest that combination therapy improves the 429 trypanocidal action of the CV analogues together with BZL. 
467
Regarding proline transport as therapeutic target, to our knowledge there are no 
480
In this work, a combined strategy involving similarity-based virtual screening 481 followed by in vitro assays was applied in order to obtain new trypanocidal less LTD-CPH-CFZ than each drug alone needed to achieve the same effect.
549
These results suggest that the combination therapy would make possible to 550 diminish the dosage of BZL and thus, the toxicity and side effects reported (6).
551
However, future studies will need to focus on the effect of the combination therapy 552 between BZL and the CV structural analogues in trypomastigotes and in infected 553 cells.
554
The final goal would be to identify new treatments based on drug repositioning 
